Fycompa Oral Suspension Launched for Patients with Swallowing Difficulty
Eisai announced the availability of Fycompa (perampanel) Oral Suspension for use in patients who have difficulty swallowing tablets or prefer liquids. The oral suspension, which was recently approved, is a bioequivalent interchangeable alternative to Fycompa tablets.
Fycompa is indicated as adjunctive therapy for the treatment of partial-onset seizures (POS) with or without secondarily generalized seizures, and primary generalized tonic-clonic (PGTC) seizures in patients with epilepsy ≥12 years old. It is a non-competitive AMPA (alpha-amino-3-hydroxy-5-
Fycompa is a CIII controlled substance already available as 2mg, 4mg, 6mg, 8mg, 10mg, and 12mg strength tablets. The new oral suspension formulation is now available as a 0.5mg/mL strength in 340mL bottles with an adapter and syringes.
For more information call (888) 274-2378 or visit Fycompa.com.